Want to see IL:TEVA full AI Analyst Report?

Teva (TEVA) Price & Analysis

61 Followers

TEVA Stock Chart & Stats

11030.00

-80.00(-0.84%)

At close: Jul 27 4:00 PM EDT

11030.00

-80.00(-0.84%)

Day’s Range― - ―

52-Week Range6,207.00 - 13,070.00

Previous CloseN/A

Volume1.19M

Average Volume (3M)1.10M

Market Cap

₪143.56B

Enterprise Value154.00B

Total Cash (Recent Filing)₪3.63B

Total Debt (Recent Filing)₪16.76B

Price to Earnings (P/E)62.9

Beta0.63

Next Earnings

Nov 03, 2026

EPS Estimate

222.2

Next Dividend Ex-DateN/A

Dividend Yield1.67%

Share Statistics

EPS (TTM)0.63

Shares Outstanding1,165,296,100

10 Day Avg. Volume1,163,263

30 Day Avg. Volume1,103,587

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)4.58

Price to Sales (P/S)1.94

P/FCF Ratio14.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₪15,024.92

Price Target Upside36.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)6.22

Revenue Forecast (FY)₪50.83B

Bulls Say, Bears Say

Bulls Say

Innovative Portfolio GrowthRapid growth in innovative medicines is shifting Teva toward differentiated products with stronger expansion potential than its mature generic base. A rising innovative revenue mix can support better margins, reinforce commercial scale, and provide a more durable platform for future growth.

Strong Cash Generation And Improving MarginsStrong free cash flow and improving gross margins indicate that the operating recovery is producing real cash rather than relying only on accounting profit. Continued cash conversion can fund product investment, support debt reduction, and expand strategic flexibility over the coming quarters.

Biosimilars Platform And Market PositionThe biosimilars portfolio adds a scalable growth pillar alongside generics and specialty medicines. Teva’s existing products, pipeline, partnerships, and leading position in several U.S. biosimilars could broaden revenue sources and strengthen its competitive position over time.

Bears Say

Elevated LeverageLeverage remains a material constraint despite balance-sheet progress. Debt service and the need to reach management’s lower leverage target can limit capital available for acquisitions, innovation, and shareholder returns, while leaving less financial cushion if earnings weaken.

Generic Revenue PressureThe loss of generic REVLIMID exposes the earnings sensitivity of Teva’s high-volume portfolio to product concentration and market competition. Even if the comparison normalizes, fewer high-value launches and pricing pressure can weigh on revenue growth and offset specialty expansion.

Approval And Payer Execution RiskTeva’s growth strategy depends on regulatory approvals, reimbursement access, and successful launches across its pipeline and specialty portfolio. Delays, restrictive payer decisions, or post-IRA pricing changes could reduce the timing and scale of expected revenue growth.

Teva News

Teva price target raised to $47 from $42 at Barclays

Barclays analyst Glen Santangelo raised the firm’s price target on Teva (TEVA) to $47 from $42 and keeps...

11d ago

TEVA

Teva price target raised to $50 from $40 at JPMorgan

JPMorgan raised the firm’s price target on Teva (TEVA) to $50 from $40 and keeps an Overweight rating...

14d ago

TEVA

Midday Fly By: SpaceX buys spectrum, Delta cuts earnings guidance

The major averages were broadly higher near noon as a rebound in tech stocks helps Wall Street bounce...

17d ago

Teva announces FDA approval for Weltruza

Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting...

17d ago

TEVA

First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo

Wells Fargo raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps...

17d ago

ARGX

TEVA

Teva call volume above normal and directionally bullish

Bullish option flow detected in Teva (TEVA) with 7,335 calls trading, 1.2x expected, and implied vol increasing over...

19d ago

TEVA

Teva announces published review on dopamine pathways in Tourette syndrome

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the Journal of Child Neurology published...

24d ago

TEVA

Teva announces new data for ecopipam

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new data for ecopipam. Presented at the...

24d ago

TEVA

Exxon Mobil downgraded, BP upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

25d ago

Teva, Samsung Bioepis expand strategic partnership to advance biosimilars

Samsung Bioepis and Teva (TEVA) Pharmaceutical Industries announced that the companies have entered into a global license, development,...

25d ago

TEVA

Salveen Richter Reiterates Buy on Teva, Sets $50 12-Month Target Backed by EV/EBITDA Valuation Ahead of Q3 Earnings

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Teva, with a price target of $50.00....

12d ago

TEVA

Teva Rated Buy on Improving Balance Sheet, Emerging Pipeline, and Modest Upside to Current Share Price

Analyst Jason Gerberry of Bank of America Securities maintained a Buy rating on Teva, with a price target...

1M ago

TEVA

Safe Pro Group (NASDAQ: SPAI) Draws WhaleWatchAlerts Attention Following Phillip Frost’s $4M Share Purchase

Austin, Texas, United States, September 15th, 2026, FinanceWire Billionaire investor Dr. Phillip Frost purchased 1 million restricted Safe...

1M ago

OPK

SPAI

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

Teva Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from...

2M ago

TEVA

TEVA FAQ

What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?

Teva Pharmaceutical Industries Limited lowest stock price was 6207.00 and its highest was 13070.00 in the past 12 months.

What is Teva Pharmaceutical Industries Limited’s market cap?

Teva Pharmaceutical Industries Limited’s market cap is ₪143.56B.

When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?

Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Nov 03, 2026 which is in 8 days.

How were Teva Pharmaceutical Industries Limited’s earnings last quarter?

Teva Pharmaceutical Industries Limited released its earnings results on Jul 29, 2026. The company reported 6.2 earnings per share for the quarter, missing the consensus estimate of 15.6 by -9.4.

Is Teva Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Teva Pharmaceutical Industries Limited pay dividends?

Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of 1.67%. See more information on Teva Pharmaceutical Industries Limited dividends here

What is Teva Pharmaceutical Industries Limited’s EPS estimate?

Teva Pharmaceutical Industries Limited’s EPS estimate is 222.2.

How many shares outstanding does Teva Pharmaceutical Industries Limited have?

Teva Pharmaceutical Industries Limited has 1,165,296,100 shares outstanding.

What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?

Teva Pharmaceutical Industries Limited reported an EPS of 6.2 in its last earnings report, missing expectations of 15.6. Following the earnings report the stock price went up 10.172%.

Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in IL:TEVA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva (TEVA) Earnings & Revenues

Historic Earnings Reports

TEVA Revenue Breakdown

54.45% North America

32.42% Europe

13.12% International Markets

TEVA Stock 12 Month Forecast

Average Price Target

15,024.92

▲(36.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6439":"6,439","11760":"11,760","17081":"17,081","9099.5":"9,099.5","14420.5":"14,420.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17080.53314,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15024.920792,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">15K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13353.871364,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">13K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6439,9099.5,11760,14420.5,17081],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12160,12538.502549230769,12917.00509846154,13295.507647692308,13674.010196923076,14052.512746153847,14431.015295384615,14809.517844615384,15188.020393846153,15566.522943076923,15945.025492307692,16323.528041538462,16702.03059076923,{"y":17080.53314,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12160,12380.378522461539,12600.757044923077,12821.135567384616,13041.514089846154,13261.892612307693,13482.271134769231,13702.64965723077,13923.028179692308,14143.406702153847,14363.785224615385,14584.163747076924,14804.542269538462,{"y":15024.920792,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12160,12251.83625876923,12343.672517538462,12435.508776307692,12527.345035076924,12619.181293846153,12711.017552615385,12802.853811384615,12894.690070153847,12986.526328923077,13078.362587692309,13170.198846461539,13262.03510523077,{"y":13353.871364,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6440,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6667,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8632,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9953,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10800,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10460,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9239,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10290,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9725,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10080,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10870,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11020,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12160,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >